TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26807640
Drug: DC-LOP (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-LOP (IV paclitaxel at 60 mg/m² followed by IV carboplatin at AUC 6 and IV pegylated liposomal doxorubicin at 30 mg/m²)
Study: 26807640
Drug: GC-LOP (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC-LOP (IV paclitaxel at 60 mg/m² followed by IV gemcitabine at 1000 mg/m²)
Study: 21142292
Drug: Intravenous microdose
Normalized name: LANCET,MICRODOT SAFETY 28G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous microdose of verapamil [0.05 mg] (period 1)
Study: 21142292
Drug: Intravenous microdose
Normalized name: LANCET,MICRODOT SAFETY 28G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous microdose of verapamil [0.05 mg] administered concomitantly with an oral therapeutic dose [80 mg] (period 2)
Study: 19074961
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of antenatal betamethasone
Study: 16773465
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture (108 g) given orally to cirrhotics
Study: 11181660
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (5 years of tamoxifen, polychemotherapy including cyclophosphamide/methotrexate/fluorouracil-like regimens, anthracycline-based therapy, or therapy based on both an anthracycline and a taxane)
Study: 27225722
Drug: Oral L-carnitine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine, 1 g/L for 3 months
Study: 25140957
Drug: GS-5806 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5806 (50 mg first dose, then 25 mg daily for 4 days)
Study: 21733370
Drug: estradiol and
Normalized name: Estradiol and Norgestimate Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol and drospirenone tablets (Angeliq)
Study: 20397455
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and herbal medicine
Study: 12571165
Drug: Metformin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin for 6 months followed by clomiphene citrate
Study: 12571165
Drug: Cost-effective analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effective analysis for medications per pregnancy in group I
Study: 10920060
Drug: Light to
Normalized name: MINERAL OIL,LIGHT TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among nondiabetic men
Study: 10920060
Drug: Light to
Normalized name: MINERAL OIL,LIGHT TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light to moderate alcohol consumption (rarely/never, monthly, weekly, daily) among diabetic men
Study: 1566986
Drug: Intravenous tubocurarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tubocurarine 0.05 mg.kg‐1
Study: 1566986
Drug: Intravenous chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chlorpromazine 0.1 mg.kg‐1
Study: 1566986
Drug: Alphatocopherol (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphatocopherol (vitamin E) 600 mg in three divided doses orally
Study: 1566986
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg orally
Study: 1566986
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium chloride 5 mg.kg‐1
Study: 30986285
Drug: Computer-assisted implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 1, n = 24)
Study: 30986285
Drug: Computer-assisted implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted implant planning based on three-dimensional (3D) computer-tomography (test group 2, n = 23)
Study: 30986285
Drug: Conventional two-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional two-dimensional radiograph and free-hand implant placement (control, n = 26)
Study: 26864301
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of fractional 1550-nm ytterbium/erbium fiber laser and 0.1% tacrolimus ointment
Study: 15213039
Drug: Lutein supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplement in oil (LS treatment, 1.7 mg lutein/d)
Study: 15213039
Drug: Yellow carrots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow carrots (YC treatment, 1.7 mg lutein/d)
Study: 15213039
Drug: White carrots
Approvals — FDA: no, EMA: no, PMDA: no
Description: White carrots (WC treatment, 0 mg lutein/d)
Study: 15213039
Drug: Yellow carrots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow carrots (YC treatment)
Study: 15213039
Drug: Lutein supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplement in oil (LS treatment)
Study: 11448369
Drug: Venlafaxine hydrochloride
Normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine hydrochloride (37.5 mg twice-daily)
Study: 9539918
Drug: Griseofulvin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (10 mg/kg/day for 8 weeks)
Study: 9539918
Drug: Terbinafine (62.5‐250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (62.5‐250 mg/day for 4 weeks)
Study: 8024798
Drug: Topical all-trans
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical all-trans retinoic acid gel (Aberel)
Study: 8024798
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid gel
Study: 2478341
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA), 5 mg/day
Study: 2478341
Drug: Previous study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous study with 50 mg/day CMA
Study: 7375
Drug: bromazepam (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromazepam (9 mg)
Study: 29947134
Drug: Bakuchiol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bakuchiol 0.5% cream applied twice daily
Study: 29947134
Drug: Retinol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol 0.5% cream applied daily
Study: 28327054
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency (LF) rTMS + physical therapy (PT)
Study: 28327054
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency (LF) rTMS + NMES + physical therapy (PT)
Study: 26126419
Drug: Cognitive Adaptation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Adaptation Training (CAT) weekly for 9 months; monthly thereafter
Study: 16507179
Drug: Midazolam (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (administered in small, divided doses over 4-5 min until Wilson sedation score reached three)
Study: 12173139
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (3 mg retinol equivalent)
Study: 7582385
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg (0.32 +/- 0.07 mg.kg‐1) as a 10 mg.ml‐1 solution
Study: 350498
Drug: Methylcysteine hydrochloride
Normalized name: Methylcysteine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcysteine hydrochloride (1200 mg daily in Week 1, 800 mg daily in Week 2, then 600 mg daily)
Study: 350498
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablets, same regimen)
Study: 28629872
Drug: Sevoflurane administered
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administered at 1 minimal alveolar concentration for 5 minutes after being weaned from CPB (group SEV)
Study: 28629872
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia maintained (group CTRL)
Study: 23412700
Drug: Camostat (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat (1.6 mg dose group)
Study: 23412700
Drug: Camostat (estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat (estimated dose of 18 μg/mL)
Study: 11394515
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg fentanyl (0.4 ml)
Study: 11394515
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (0.4 ml)
Study: 9972118
Drug: Sub-antimicrobial-dose doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-antimicrobial-dose doxycycline (SDD) 20 mg BID
Study: 8071758
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin A supplementation
Study: 10933649
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg every 6 h for 7 days)
Study: 3179171
Drug: Phenytoin sodium
Normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin sodium (400 mg single oral dose)
Study: 5309085
Drug: Two different
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different vaccines
Study: 31443102
Drug: 1.8 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 × 10^10 CFU B. infantis EVC001 daily for 21 days
Study: 28421383
Drug: Guanfacine XR
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine XR 1 mg orally on Day 1, followed by 1 mg (Days 4-8), 2 mg (Days 9-13), 3 mg (Days 14-18), and 4 mg (Days 19-23) once daily
Study: 25966824
Drug: Individualized, formula-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, formula-based dosing of Genotropin®
Study: 25966824
Drug: Standard weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based dosing of Genotropin®
Study: 24088130
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing (genetic plus clinical information)
Study: 19371312
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (0.2 mg)
Study: 16877722
Drug: Chronomodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronomodulated infusion of fluorouracil, leucovorin, and oxaliplatin for 4 days (chronoFLO4)
Study: 16877722
Drug: Chronomodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronomodulated infusion (chronoFLO4) in women
Study: 16877722
Drug: Chronomodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronomodulated infusion (chronoFLO4) in men
Study: 10902785
Drug: QUICKI (1/[log(I(0))
Approvals — FDA: no, EMA: no, PMDA: no
Description: QUICKI (1/[log(I(0)) + log(G(0))])
Study: 9076577
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment
Study: 9076577
Drug: Before calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before calcitriol treatment
Study: 8222495
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Study: 8222495
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg twice a day for 2 weeks after 1 week of placebo or indomethacin
Study: 8222495
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg twice a day for 3 weeks
Study: 18672472
Drug: Fampridine 10
Normalized name: dalfampridine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine 10 mg twice daily
Study: 18672472
Drug: Fampridine 15
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fampridine 15 mg twice daily
Study: 18672472
Drug: Fampridine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine 20 mg twice daily
Study: 15906951
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) (n=139)
Study: 15906951
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus 5 mg medroxyprogesterone acetate (MPA) (n=97)
Study: 15906951
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus 10 mg MPA (n=109)
Study: 12526069
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg/day for 3 days
Study: 12888586
Drug: Co-amoxiclav 45
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 45 mg/kg/day for 10 days
Study: 10531771
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg i.v.
Study: 9753705
Drug: Hyoscine N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butylbromide 20 mg i.v.
Study: 7910470
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg) vs Suriclone (0.4 mg)
Study: 3111101
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dexamethasone
Study: 3111101
Drug: Double doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double doses of dexamethasone
Study: 30909787
Drug: Local intra‐arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intra‐arterial prostaglandin therapy
Study: 31160549
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (Arm 1: 0.2 mg/kg/day, Arm 2: 0.15-0.175 mg/kg/day, Arm 3: 0.2 mg/kg/day delayed until Day 5)
Study: 31160549
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (early lower-dose and delayed higher-dose regimens)
Study: 31160549
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (early-lower tacrolimus arm with older donors, delayed higher-dose tacrolimus arm with younger donors)
Study: 25961367
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to the diagnostic algorithm
Study: 21392712
Drug: High-calcium (HC)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium (HC) diet supplying 1,500 mg calcium/d
Study: 10668706
Drug: Lu25-109 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu25-109 25 mg tid
Study: 10668706
Drug: Lu25-109 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu25-109 50 mg tid
Study: 10668706
Drug: Lu25-109 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu25-109 100 mg tid
Study: 9058328
Drug: No agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No agent (VC)
Study: 23169319
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg SC abatacept weekly
Study: 23169319
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SC adalimumab biweekly
Study: 21494062
Drug: 16-session disorder-specific
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-session disorder-specific SAD treatment program including parent training and classical cognitive-behavioral therapy (CBT) components
Study: 17882417
Drug: Dalteparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5,000 U sub-Q daily)
Study: 9363277
Drug: Single breath
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single breath vital capacity rapid inhalation induction (VCRII)
Study: 9363277
Drug: Multiple deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple deep breaths inhalation induction (DBI)
Study: 1489025
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (n = 11) with background infusion of 4 ml.h-1 of bupivacaine 0.125% with fentanyl 1 microgram.ml-1 and 3-6 ml bolus doses as required (15 min lockout interval)
Study: 1489025
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion epidural analgesia (n = 12) with continuous infusion starting at 10 ml.h-1, adjustable up to 25 ml.h-1
Study: 2872336
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac 60 ml plus water 480 ml followed by activated charcoal 50 g
Study: 27990505
Drug: GENESIS Implant
Normalized name: Genesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: GENESIS Implant System
Study: 27990505
Drug: PRIMA Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMA Implant System
Study: 24928953
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor blockade (bosentan)
Study: 11758896
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (Pulmicort Turbuhaler) 800 microg/day for 4 weeks
Study: 11758896
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (Talotren tablets, 200 mg twice daily) for 4 weeks
Study: 7964811
Drug: Tizanidine 2
Normalized name: tizanidine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 2 mg
Study: 24822235
Drug: Tizanidine 4
Normalized name: tizanidine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 4 mg
Study: 7964811
Drug: Tizanidine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 8 mg
Study: 25128802
Drug: Intranasal FluMist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal FluMist seasonal influenza vaccine (3 doses on Days 0, 28, and 56) + rintatolimod (50 μg, 200 μg, or 500 μg)
Study: 25128802
Drug: Intranasal FluMist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal FluMist seasonal influenza vaccine + rintatolimod
Study: 21910949
Drug: Galacto-oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-oligosaccharides (GOS) 4 g in juice, consumed twice daily for 3 weeks
Study: 21910949
Drug: Placebo, consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, consumed twice daily for 3 weeks
Study: 16055308
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Haloperidol
Study: 12109650
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Gammalinolenic acid (GLA) extracted from Evening Primrose Oil
Study: 12109650
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Gammalinolenic acid (GLA)
Study: 10405233
Drug: Acetaminophen (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1.0 g) with Lansoprazole (30 mg) after pretreatment with 30 mg once daily for 2 days
Study: 10405233
Drug: Acetaminophen (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1.0 g) alone (control session)
Study: 8639197
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg)
Study: 2123602
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous heparin anticoagulation (5,000 U bolus followed by 1,000 U/hour)
Study: 31364228
Drug: OA-enriched olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA-enriched olive oil (55 mL/day, equivalent to 30 mg OA/day)
Study: 21214497
Drug: Broadband light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broadband light (400-800 nm) at 180 mW/cm², twice a day for 4 min/session
Study: 17926613
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy with 'Hongwai Zhike Plaster' at Dazhui (GV 14), Dingchuan (EX‐B 1), Tiantu (CV 22) plus common treatment.
Study: 17926613
Drug: Common treatment
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment (giving up smoking, proper exercise).
Study: 17926613
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy.
Study: 28152236
Drug: N-acetylcysteine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine treatment
Study: 2695415
Drug: Cefaclor, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 40 mg/kg/day in 3 divided doses for 10 days
Study: 2695415
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX), 1 mg/kg/day (trimethoprim 8 mg, sulfamethoxazole 40 mg) in 2 divided doses for 10 days
Study: 321094
Drug: Low-dose oxytetracycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytetracycline (250 mg twice a day)
Study: 321094
Drug: Sustained-release tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release tetracycline hydrochloride
Study: 321094
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment of asymptomatic contacts
Study: 28438152
Drug: Intervention (community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (community pharmacist-led Medicines Use Review)